2023
P105: Measuring clinically relevant change in apathy symptoms in ADMET 2
Tuma S, Herrmann N, Perin J, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, CraG S, Levey A, Shade D, Mintzer J, Lanctôt K. P105: Measuring clinically relevant change in apathy symptoms in ADMET 2. International Psychogeriatrics 2023, 35: 126-127. DOI: 10.1017/s1041610223002569.Peer-Reviewed Original ResearchImpression of ChangeChange scoresMeasure clinically relevant changesNPI apathy scoreEffect sizeClinical impression of changeMinimal clinically significant improvementClinical Global Impression of ChangeSpearman correlationClinical Global ImpressionClinically significant improvementSix-month visitGlobal Impression of ChangePsychosocial interventionsClinically relevant changesApathy symptomsAssessment ScaleAssessment Change ScoreMann-Whitney U testComplete dataWorsened groupParticipantsApathyNo changeTreatment trials
2020
Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab
Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Farlow M, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Salloway S, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Andersen S, Holdridge K, Mintun M, Sims J, Yaari R, Baudler M, Delmar P, Doody R, Fontoura P, Kerchner G, Team D. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.041129.Peer-Reviewed Original ResearchDisease prevention trialsPrevention trialsAlzheimer's disease prevention trialsDifferent antigenic targetsSignificant neuronal lossKey secondary outcomesParallel-group trialAD prevention trialsAdaptive platform trialFuture clinical trialsBeta monoclonal antibodyTiming of treatmentSymptomatic ADLast patientSecondary outcomesSymptom onsetNeuronal lossTop-line resultsTreatment trialsTau-PETAntigenic targetsBrain damageClinical trialsPlatform trialsAD hypotheses